A producer of pharmaceutical grade products, Betterlife, announced the acquisition of Swiss-based Solmic, aiming to tap into the latter’s formulation technology suitable for orally-delivered cannabidiol (CBD)-based products.
Solmic’s technology is based on the production of stable micelles containing water insoluble compounds, which can ‘greatly’ enhance the bioavailability of fat soluble ingredients by as much as 15 times, allowing for accelerated uptake of the ingredients in the human digestive tract, according to Betterlife.
The Grocer, FoodNavigator, NutraIngredients and CosmeticsDesign are co-hosting a two-day CBD Global Summit in London, March 16-17, 2020. For more details visit the CBD Global Summit website.
Uptake from the intestinal tract functions well with water soluble ingredients, however in the case of fat soluble or resin-like compounds, such as essential oils, vitamin E, D, as well as ‘almost all’ natural extracts, the ingredients need to be solubilized, according to Solmic.
This process is naturally achieved by bile salts, although only in younger patients, and with this process only resulting in 5-15% uptake.
Solmic’s technology has the potential to enhance the uptake of water-insoluble ingredients by keeping lipid-soluble compounds trapped in micelles and thus increasing the molecules’ uptake from the intestine, increasing the bioavailability of products.
Ahmad Doroudian, Betterlife’s interim CEO, stated that the acquisition of these patents will allow the company to commercialize products that deliver orally bioavailable CBD ‘like no other product’ currently on the market.
He added that products utilizing this formulation technology are scheduled to be introduced onto the market by Betterlife over the next two to three months.
